Hidradenitis Suppurativa: A New Indication for Adalimumab

Tuesday, June 12, 2018

In this edition of the “Peer to Peer” audiocast series, Dr. Vincent DeLeo speaks with Dr. Jashin J. Wu about adalimumab for the treatment of hidradenitis suppurativa (HS). Dr. Wu reviews the specifics of the approval of adalimumab for HS, including dosing information. He also discusses his own treatment algorithm for managing patients with HS. Finally, Dr. Wu speculates on future targets for current biologics that already have been approved for other indications.

Podcast Participants

Vincent A. DeLeo, MD
Vincent A. DeLeo, MD, is from the Keck School of Medicine of the University of Southern California, Los Angeles, and the Icahn School of Medicine at Mount Sinai, New York, New York. He also is the editor in chief of Cutis and the author of more than 200 publications. He is a leading expert on contact dermatitis, sunscreens, and photosensitivity. Dr. DeLeo is a consultant for Estée Lauder.